/ONCR

ONCR Stock - Oncorus, Inc.

Q: What is the analyst price target for ONCR?

Analyst price target information is not currently available for ONCR.

Q: What is ONCR's market cap?

Market capitalization information is not currently available for ONCR.

Healthcare|Biotechnology|NASDAQ

$0.13-3.08%

$0.00 (-3.08%) • Dec 29

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.14

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ONCR

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.95

52W High$0.47

52W Low$0.01

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-76,537,000	$-64,818,000	$-37,153,000	$-31,166,000	$-18,578,000
Net Income	$-78,307,000	$-64,697,000	$-46,783,000	$-30,195,000	$-18,046,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-3.02	$-2.56	$-7.69	$-2.42	$-1.97

Company Overview

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Visit Website

Earnings History & Surprises

ONCR

Beat Rate

25%

Last 12 quarters

Avg Surprise

-193.1%

EPS vs Estimate

Beats / Misses

3/7

2 met exactly

Latest EPS

$-0.74

Q3 2023

EPS Surprise History

Q4 21

0.0%

$-0.65vs$-0.65

Q1 22

-8.5%

$-0.77vs$-0.71

Q2 22

+11.5%

$-0.69vs$-0.78

Q3 22

0.0%

$-0.74vs$-0.74

Q4 22

+1.3%

$-0.76vs$-0.77

Q1 23

-3.8%

$-0.81vs$-0.78

Q2 23

-68.6%

$-1.18vs$-0.70

Q3 23

-21.3%

$-0.74vs$-0.61

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2024	May 20, 2024	—	—	—	—
Q1 2024	Mar 22, 2024	—	—	—	—
Q1 2024	Jan 3, 2024	$-0.50	—	—	—
Q3 2023	Aug 3, 2023	$-0.61	$-0.74	-21.3%	✗ MISS
Q2 2023	May 22, 2023	$-0.70	$-1.18	-68.6%	✗ MISS
Q1 2023	Mar 24, 2023	$-0.78	$-0.81	-3.8%	✗ MISS
Q4 2022	Nov 2, 2022	$-0.77	$-0.76	+1.3%	✓ BEAT
Q3 2022	Aug 4, 2022	$-0.74	$-0.74	0.0%	= MET
Q2 2022	May 4, 2022	$-0.78	$-0.69	+11.5%	✓ BEAT
Q1 2022	Mar 9, 2022	$-0.71	$-0.77	-8.5%	✗ MISS
Q4 2021	Nov 3, 2021	$-0.65	$-0.65	0.0%	= MET
Q3 2021	Aug 4, 2021	$-0.58	$-0.60	-3.4%	✗ MISS
Q2 2021	May 4, 2021	$-0.54	$-0.53	+1.9%	✓ BEAT
Q1 2021	Mar 10, 2021	$-0.49	$-0.56	-14.3%	✗ MISS
Q4 2020	Nov 11, 2020	$-0.94	$-21.73	-2211.7%	✗ MISS
Q2 2020	Jun 30, 2020	—	$-0.43	—	—
Q1 2020	Mar 31, 2020	—	$-0.63	—	—
Q4 2019	Dec 31, 2019	—	$-0.71	—	—
Q3 2019	Sep 30, 2019	—	$-0.61	—	—